Catalog No.
KDJ70104
Description
PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human CD274 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Pacmilimab in the sample competitively binds to the pre-coated protein with biotin-labeled Pacmilimab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Pacmilimab bound in the initial step. The color development is stopped and the intensity of the color is measured.
Applications
Used for the quantitative determination of Pacmilimab concentration in serum and plasma.
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
781.25 - 50,000 ng/mL
Sensitivity
390.71 ng/mL
Precision
Intra-Assay Precision (Precision within an assay): <20%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <20%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
|
|
Intra-Assay Precision |
Inter-Assay Precision |
||||
|
Sample |
1 |
2 |
3 |
1 |
2 |
3 |
|
n |
16 |
16 |
16 |
24 |
24 |
24 |
|
Mean (ng/mL) |
28446.9 |
8449.3 |
2052.5 |
29980.9 |
8092.9 |
1840.2 |
|
Standard deviation |
1849.7 |
438.7 |
251.4 |
2275.9 |
736.6 |
318.0 |
|
CV (%) |
6.5 |
5.2 |
12.2 |
7.6 |
9.1 |
17.3 |
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.
Alternative Names
CX-072, CAS: 2145091-51-4
Background
Pacmilimab (CX-072) is a Probody therapeutic directed against PD-L1 designed and developed by CytomX. Pacmilimab is engineered to be conditionally activated in the tumor microenvironment by tumor-associated proteases and to remain predominantly masked in the circulation. In preclinical studies, pacmilimab induced anti-tumor responses comparable to those of the parental anti-PD-L1 antibody and demonstrated reduced toxicity.
For research use only. Not for human or drug use.
